Skip to main content
HIV/AIDS (Auckland, N.Z.) logoLink to HIV/AIDS (Auckland, N.Z.)
. 2021 Aug 11;13:801–812. doi: 10.2147/HIV.S320601

Incidence and Predictors of Loss to Follow-Up Among Children Attending ART Clinics in Northeast Ethiopia: A Retrospective Cohort Study

Tiruye Menshw Snr 1,, Shiferaw Birhanu 2, Tigist Gebremaryam 3, Worke Yismaw 1, Aklilu Endalamaw 2,4
PMCID: PMC8364847  PMID: 34408500

Abstract

Background

It is known that antiretroviral therapy reduces the transmission of human immunodeficiency virus and AIDS-related morbidity. The coverage of HIV drugs is increasing to control further spread of HIV and children living with HIV are the target groups in using these medications. However, loss to follow-up remains a critical challenge among these groups of the population. The aim of this study was therefore to assess the incidence and predictors of loss to follow-up among children attending antiretroviral therapy clinics.

Methods

A ten-year institution-based retrospective cohort study was employed among 448 children enrolled in antiretroviral therapy. Data were entered and cleaned using EpiData version 3.1 and then exported to STATA version 14 for further statistical analysis. The Kaplan–Meier survival curve was used to estimate the survival time and the Log rank test was used to compare the survival time between different categories of the explanatory variables. Multivariable Cox proportional hazards model was fitted to identify predictors of loss to follow-up and p-value < 0.05 was considered statistically significant.

Results

The incidence rate of loss to follow-up was 6.3 per 100 children years of observation. Being male (AHR = 2.1, CI = 1.37, 3.34), aged 1–5 years (AHR = 1.6, CI = 1.05, 2.46), poor adherence to antiretroviral therapy (AHR = 6.6; CI = 4.11, 10.66), fair adherence to antiretroviral therapy (AHR = 2.2; CI = 1.13, 4.20), regimen was not changed (AHR = 4.1; CI = 2.59, 6.45), World Health Organization stage III and IV (AHR = 2.2; CI = 1.40, 3.33) and height for age <−2 z score (AHR = 2.2; CI = 1.43, 3.44) were predictors of loss to follow-up.

Conclusion

Nearly seven out of 100 HIV-infected children were lost to follow-up from their link to ART clinics within a one-year follow-up. Non-modifiable demographic characteristics, clinical stage and nutritional status, and ART-related variables were associated with children’s loss to follow-up. Therefore, close monitoring of the “at risk” groups might decrease the rate of loss to follow-up. Improving adherence to antiretroviral therapy and nutritional support are also recommended.

Keywords: incidence, predictors, loss to follow up, Ethiopia

Background

Since the beginning of the epidemic, 74.9 million people have been infected with HIV and 32 million people have died worldwide due to AIDS-related diseases.1 Globally, 37.9 million people were living with HIV by the end of 2018, and 1.7 million were children among HIV cases in the same year.2 More than 1500 children become infected with HIV every day. The vast majority (more than 90%) acquire the infection from their mother, so mother to child transmission is the highest contributing factor to pediatric HIV infections.2,3 Though the burden of the HIV epidemic is varied across countries and regions, an estimated 0.8% of adult populations are living with HIV worldwide which accounts for the significant number of HIV-infected children being adults after few years.3

Sub-Saharan Africa is a region most affected by HIV.4 Ethiopia is one of the Sub-Saharan African countries where it is challenging to decrease HIV across its administrative areas.5 Ethiopian demographic and health survey report showed there is a variation of HIV prevalence among the different settings. Notably, frequently reported in the western part (4.8%) and the capital city, Addis Ababa (3.4%), and lower prevalence existed in the southern (0.4%) and eastern parts (< 0.1%) of the country.6 According to the Ethiopian public health institution report, 45,824 were children among all 691,362 HIV cases by the end of 2019.7

The health sector has prepared to respond to HIV, as one of the targets to halt HIV epidemic by 2030.8 Also, Ethiopia is implementing several strategies to end the HIV epidemic by 2030. These are, by the end of 2020: plan to reduce 70% of new infections and 80% of HIV-related deaths, to enroll 85% of children with HIV in ART, and to achieve the three 95s’ targets; 95% of all people knowing their HIV status, 95% of HIV positive people having access to treatment, and 95% of all people receiving ART will have viral suppression.5,9–11 To achieve this goal, HIV infected patients should be put on HIV medications and loss to follow up (LTFU) after linked to the ART clinic should be prevented by fostering the health care system. Antiretroviral therapy (ART) is essential for children to have a long life by reducing viral load and disease progression.12 Without accessing ART and regular medical supervision, HIV-infected children are more vulnerable to complicated clinical outcomes, including death.13–15

The literature shows that high attrition within PMTCT programs could be due to LTFU rather than mortality. This shows non-retention of mothers in PMTCT programs is another contributor to the loss to follow-up of children within ART care. The quality and effectiveness of PMTCT services should be assessed on the basis of the number of mother-child pairs who are receiving consistent follow-up and antiretroviral treatment, and the number of confirmed HIV-1-negative children born to HIV-1-positive women.16

Loss to follow-up (LTFU) is a critical barrier to HIV care and treatment.17 A significant number of children drop out from the treatment cascade.18 Globally, 14% and 28% of children were LTFU from the treatment cascade at one and two years after starting ART, respectively.13 Similarly, in Sub-Saharan Africa, 20–40% of children with HIV were LTFU.19,20 Children on ART who become LTFU are more at risk of developing drug-resistant viruses than those who remain on ART as a result. Due to this, children’s quality of life might be impaired and their survival time might also be shorter.21,22

Several studies revealed that there was a significant number of children LTFU from their ART clinic. Studies in Asia and Africa showed that 69% of LTFU occurred in the first 3 and 6 months of ART.23 In South Africa, 8.4 per 100 children years of observation and 5 per 100 children per year were LTFU in the first and second years, respectively24 and, in Ethiopia, 6.26 per 100 children per year was documented.25 LTFU could be affected by the complex interplay of self-care, community factors, care delivery, and the drug itself.26 According to data from children at baseline, the variables associated with LTFU from the previous studies were: younger age, lower CD4 cell count during ART initiation, WHO stage III/IV, weight for age ≤ 2, short duration on ART, hemoglobin level <8g/dl, living with non-educated caregiver, and disclosure of HIV status.27–32

To decrease the loss of children from the ART program, several African regions, including Ethiopia, have applied different mechanisms. Offering free ART, decentralization of services, creating awareness using religious or community leaders and other stakeholders, counseling, and phone calls or mobile short message left for a caregiver were applied to retain children in the ART program.33,34

LTFU is a critical barrier complicating clinical outcome in HIV treatment program and identifying whether modifiable or non-modifiable factors were associated with LTFU is fundamental for designing effective patient retention strategy.35 There is limited evidence regarding the predictors of loss to follow-up among children attending ART clinics in Ethiopia. Therefore, we assessed the incidence and predictors of LTFU among children attending ART clinics in the Northeastern parts of Ethiopia.

Methods

Study Setting

The sample was from the Dessie referral hospital, which is a government hospital found in northeast Ethiopia that serves a catchment population of seven million. The hospital is in Dessie town, which is 401 km from the capital city of Addis Ababa. The hospital has been providing ART services for people living with HIV since 1995 Ethiopian calendar, and the ART case team comprises a variety of trained health professionals (four physicians, twelve nurses, three pharmacists, four laboratory technicians, four data clerks, and two ART education adherence counselors). About 1600 ART users were recorded in the last ten years and most of them come to the hospital according to their appointments with their parents. The service given in the ART clinic includes; ART provision, management of cases including: OIs, side effects, nutritional support, counseling and health education. The patients do not pay when they come for ART services because the service is supported by government and NGOs.

Study Design and Period

An institution-based retrospective cohort study was done from February 1 to 27/2020 which included patient charts from January 2010 to January 2020.

Sample Size Determination and Sampling Procedures

For the first objective, a single population formula was used to calculate the sample size by considering the following statistical assumption: P= cumulative incidence of LTFU among children on ART 8.63% study done in Ethiopia.36 Z α/2 = the corresponding Z score of 95% CI, d= margin of error (5%) and in= sample size n= (Z α/2)2*p (1-p) /d2 n= (1.96)2*0. 863(1–0.863)/ (0.05)2= 182. For the second objective, the sample size was determined using Epi info version 7.2 by considering the following predicates: underweight, hemoglobin level and taking cotrimoxazole in a study conducted in Ethiopia.39 With 95% CI, 80% power and ratio of exposed to unexposed 1:1, the highest sample size was 488, so we considered it as a final sample. The medical registration numbers of under-15 year old children who started ART were collected from the database. Then, the computer-generated method was used to select random medical registration numbers.

Data Collection Instrument and Procedure

The data extraction tool was developed from the standardized ART entry and follow-up form of the Ethiopia ministry of health and used by the ART clinic during data collection, which consists of Part-I; social, demographic characteristics of the child and caregiver, part-II; baseline clinical, laboratory and ART related information, part-III; ART treatment and other medication related information and part-IV; patient follow-up information (completed from ART follow-up form) recent results.

First, the patient record was observed and an appropriate data extraction format was prepared in the English version. Data collectors were used and the data collection tool to collect the information from children’s charts. Charts were retrieved using the children’s registration number, which was found in the database in the electronic system, charts with incomplete intake forms were excluded from the study and one data clerk supported by identifying registration number of the charts. Necessary data were extracted by reviewing children’s ART cards. Loss to follow-up was confirmed by reviewing medical registration in the hospital or registration by ART adherence supporters. The data were collected by four experienced personnel with Bachelor of Science degree in nursing who had been trained in comprehensive HIV care and were involved in the HIV care clinic. Ten percent of the sample size charts were checked to ensure consistency of the data extraction tool before starting data collection. One person with Master of Science degree in nursing closely supervised the entire data collection process. One day training was given to both data collectors and supervisor. Data quality was also ensured through designing proper data collection tool and continuous supervision. Codes were given for checklists. All collected data were checked for completeness by data collectors and supervisor every day.

Variables

Socio-Demographic Characteristics

Socio-demographic characteristics included: age of children, sex of children, religion of care giver, relation of caregiver to child, place of delivery, residence, marital status of caregiver, occupation of caregiver, parent status, parent’s HIV status, age of parent/caregiver, and sex of care giver. Clinical and laboratory predictors: WHO stage, CD4 count, hemoglobin level, functional status (for >5 years), developmental status (<5 years) and opportunistic infection, drug side effects, and adherence to ART.

ART and Other Medication Predictors

Prophylaxis (CPTand INH), duration of ART treatment, ART regimen and time to ART initiation). Nutritional predictors: undernourished (wasting, stunting, underweight and thinness).

Operational Definition

Loss to follow-up: child on ART who has not visited the clinic in the past 30 days and more, and not documented as died or transferred out to another ART clinic considered LTFU.37

Transferred out: those who were transferred to other health care facilities.

Event: LTFU of children on ART.

Censored: when children on ART died, were transferred out to other health institution, or continued to attend an ART clinic even after the end of the study.

Duration of ART: the time between ART’s start date and date of the last contact with the health facility during data collection.

Adherence: means taking the right ARV medication, at the right dose, at the right time every day and exactly as prescribed for the rest of your life. Described as good if adherence was ≥95% (1 dose of 30 doses or 2 doses of 60 doses missed), fair if adherence was between 85 to 94% (2 to 4 doses of 30 doses or 4 to 189 doses of 60 doses missed) and poor if adherence was <85% (≥5 doses of 30 doses or ≥10 doses of 60 doses missed).35

Data Analysis

The data were checked for completeness, consistency and then, coded and entered using Epi data version 3.1. Afterward, it was cleaned and analyzed using STATA version 14. Descriptive statistics were computed to determine the frequencies and summary statistics. Anthroplus software was used to generate Z scores to categorize nutritional status by considering weight-for-age, height-for-age, weight-for-height, and body mass index for age. The Kaplan–Meier survival curve was used to estimate survival time after initiation of ART, and the Log rank test was used to compare survival curves of different categorical explanatory variables. The Cox proportional hazard model was used to assess predictors of LTFU. To see the effect of predictors on the time of LTFU, a Bivariate Cox-proportional hazard regression model was fitted for each explanatory variable. Those variables with p-value ≤ 0.25 in the bivariate analysis were fitted to the multivariate Cox-proportional hazard regression model. Cox proportional hazard model assumption was checked using scaled Schoenfeld residual test and graphically with log-log Cox adjusted survival estimate. The model fitness was checked using Cox–snell residuals test. Variables with P-value < 0.05 were considered statistically associated with LTFU.

Ethical Consideration

Ethical approval for the research paper was obtained from the ethical review committee of Bahir Dar University College of medicine and health science and then, a formal letter was written by the department of pediatrics and child health nursing in Dessie referral hospital. After that the letter was taken to Dessie referral hospital’s director and the respective head. And the study was conducted in accordance with the Declaration of Helsinki. During the data collection time, the objective of the study was clearly explained to data collectors and supervisor and the names of children were not written.

Results

Sociodemographic Characteristics of Children on ART

Among 488 children who participated in the study, 52.9% were male. The majority (76%) were of urban residency, and 85.2% were living with their parents. The median age with interquartile range (IQR) of children at the beginning of the follow-up was 8 years (IQR= 6.4) (Table 1).

Table 1.

Baseline Sociodemographic Characteristics of Children on ART in Northeast Ethiopia, 2020

Variable Frequency Percent
Sex of children Male 258 52.9
Female 230 47.1
Age of children ≥ 5 years 341 69.5
1–5 years 125 25.6
< 1 years 22 4.5
Relation of child to care giver Parent 416 85.2
Guardian 72 14.8
Religion of parent/care giver Muslim 299 61.3
Orthodox 171 35.0
Other* 18 3.7
Residence Urban 371 76
Rural 117 24
Age of parent/care giver ≥ 35 years 258 52.9
< 35 years 230 47.1
Sex of parent/care giver Male 125 25.6
Female 363 74.4
Marital status of caregiver Married 341 69.9
Single 18 3.7
Widowed 74 15.1
Divorced 55 11.3
HIV status of parent/caregiver Both parents positive 148 30.3
Mother positive 241 49.4
Father positive 29 5.9
Father negative 7 1.4
Care giver positive 1 0.2
Care giver negative 24 4.9
Unknown 38 7.8
Parent status Both alive 348 71.3
Only mother alive 57 11.7
Only father alive 29 5.9
Both died 33 6.8
Unknown 21 4.3
Occupation of parent /care giver Farmer 94 19.3
Merchant 92 18.9
Government employee 94 19.3
Daily worker 59 12.1
House wife 145 29.7
Other ** 4 0.8
Place of delivery of child Health facility 237 48.6
Home 251 74.4

Notes: *Catholic and protestant. **Students and waiters.

Baseline Clinical, Laboratory, and ART Information of Children on ART

During ART initiation, 73.2% of children had opportunistic infections. Nearly half (48.2%) of children were eligible for ART treatment based on the low level of CD4 count (Table 2).

Table 2.

Baseline Clinical, Laboratory, and ART Information of Children on ART in Northeast Ethiopia, 2020

Variable Frequency Percent
Presence of OIs at base line Yes 356 73.2
No 132 26.8
Type of OIs Pneumonia 66 18.9
Pulmonary tuberculosis 29 8.1
Upper respiratory tract infection 45 12.6
Unexplained wasting and stunting 4 1.1
Diarrhea 56 15.7
Unexplained Fever 26 7.3
Herpes zoster 44 12.3
Oral candidiasis 25 7
Skin dermatitis 49 13.7
Other* 13 3.64
Functional status ≥ 5 years (n=341) Working 324 95
Ambulatory 10 2.9
Bed-ridden 7 2.1
Developmental status < 5 years (n=147) Appropriate 121 82.3
Delayed 24 16.3
Regressed 2 1.4
WHO staging Stage I 134 27.5
Stage II 171 35
Stage III 166 34
Stage IV 17 3.5
Hemoglobin level ≥ 10 mg/dl 431 88.3
< 10 mg/dl 57 11.7
CD4 count ≥350 cells 227 46.5
< 350 cells 261 53.5
Eligibility criteria Clinical (WHO staging) 50 10.2
CD4 count 235 48.2
Without criteria 139 28.5
DBS positive 28 5.7
Both clinical and CD4 count 36 7.4
Baseline regimen 4a(d4t-3TC-NVP) 116 23.8
4b(d4t-3TC-EFV 51 10.5
4c(AZT-3TC-NV) 137 28.1
4d(AZT-3TC-EFV 88 18
1e(TDF-3TC-EFV) 51 10.5
1h(ABC-3TC-NVP) 9 1.8
1g(ABC-3TC-EFV) 15 3.1
4g(ABC-3TC-LPV/r) 17 3.5
Other (1c,4i,4j) 4 0.8
Taking prophylaxis Yes 452 92.6
No 36 7.4
Type of prophylaxis CPT 440 96.3
INH 13 2.8
Both CPTand INH 4 0.9
Side effects Yes 34 7
No 454 93
Type of side effects Anemia 16 47
Rash 14 41.2
Eye discharge 2 5.9
Other** 2 5.9
Regimen change Yes 281 57.6
No 207 42.4
Reason for change Drug side effects 34 12
New drug availability 104 36.8
Drug out of stock 82 29
New tuberculosis 6 2.1
Virologic failure 25 8.8
Weight > 25 kg 32 11.3
Adherence level Good 406 83.2
Fair 38 7.8
Poor 44 9

Notes: *HIV wasting syndrome, extra pulmonary tuberculosis, parotid enlargement; **fatigue and nausea.

Nutritional Information of Children on ART

From the study participants, 17.2% were stunted (Table 3).

Table 3.

Nutritional Information of Children on ART in Northeast Ethiopia, 2020

Variable Frequency Percent
Weight for height/length (<5 year) Normal 122 83
Wasted 25 17
Weight for age (age<10 year) Normal 267 75.4
Underweight 87 24.6
Body mass index for age (≥ 5 years) Normal weight 299 87.7
Thin 42 12.3
Height/length for age (<15 years) Normal 404 82.8
Stunted 84 17.2

Incidence of Loss to Follow-Up After ART Initiation

Of the 488 children on ART, 61.68% were continuing attending ART clinics at the end of the study; 15.37% were transferred out, and 2.25% died. Using cumulative incidence, 20.7% (95% CI=17.20, 23.80) were LTFU from ART clinic. The overall loss to follow-up incidence density rate (IDR) in the cohort was 6.3 (95% CI = 5.21, 7.77) per 100 children years of observation.

Predictors of Loss to Follow-Up

In the Bivariate analysis, the Cox proportional hazard model showed sex of a child, age of children between 1–5 years, residence, taking prophylaxis, change of regimen, CD4 count, WHO stage, hemoglobin level, adherence level, and height-for-age were statistically significant predictors of loss to follow-up. In the multivariable analysis, sex of a child, age of children between 1–5 years, WHO stage, adherence to ART, height-for-age and regimen change were predictors of loss to follow-up.

Children aged between 1–5 years had an increased hazard of LTFU of 1.6 times (95% CI =1.05, 2.46) compared to those aged ≥ 5 years. Male children were 2.1 (95% CI= 1.37, 3.34) times more prone to be LTFU than females. The hazard of LTFU in children who had WHO stage III and IV was 2.2 (95% CI=1.40, 3.33) times higher than those who had WHO stage I and II. Having poor adherence to ART had 6.6 (95% CI =4.11, 10.66) times increase in hazard to be LTFU among children as compared to good adherence to ART, and also children who had fair adherence to ART were 2.2 (95% CI=1.14,4.20) times more at risk of LTFU compared to those who had good adherence. The hazard of LTFU in children whose nutritional status was stunted (HFA<-2Zscore) was 2.2 (95% CI=1.43, 3.44) times higher than their counterparts. Children whose regimen had not been changed were 4.1 (95% CI = 2.59, 6.45) times more at risk of LTFU as compared to those whose regimen had been changed (Table 4).

Table 4.

Cox Regression Analysis for Predictors of Loss to Follow-Up Among Children on ART in Northeast Ethiopia, 2020

Variable Status CHR with CI AHR with CI P-value
LTFU Censored
Age ≥5 years 58(17%) 283(83%) 1 1
  1–5 years 39(31.2%) 86(68.8%) 1.9(1.28,2.90) 1.6(1.05, 2.46) 0.030*
  <1 years 4(18.2%) 18(81.8%) 1.2(0.43, 3.28) 0.6 (0.21,1.94) 0.426
Sex: Male 71(27.5%) 187(72.5%) 2.4(1.55–3.65) 2.1(1.37, 3. 34) 0.001**
  Female 30(13%) 200(87%) 1 1
Residence: Urban 66(17.8%) 305 (82.2%) 1 1
     Rural 35(29.9%) 82(70.1%) 2(1.34–3.04) 1.3 (0.88,2.06) 0.176
Taking prophylaxis
 Yes 88(19.5%) 364 (80.5%) 1 1
 No 13(36.1%) 23(63.9%) 2.7(1.52,4.91) 0.9(0.46,1.71) 0.718
Regimen change
 Yes 43(15.3%) 238(84.7%) 1 1
 No 58(28%) 149(72%) 4.3(2.84–6.41) 4.1(2.59,6.45) 0.000**
CD4 count
 ≥350 cells 28(12.3%) 199(87.7%) 1 1
 < 350 cells 73(28%) 188(72%) 2 (1.28–3.06) 1.5(0.93, 2.41) 0.094
Hemoglobin
 ≥10 mg/dl 75(17.4%) 356(82.6%) 1 1
 <10 mg/dl 26(45.6%) 31(54.4%) 2.7(1.73, 4.23) 1.3 (0.81, 2.16) 0.267
Height/L for age
 Normal 63(15.6%) 341(84.4%) 1 1
 Stunted 38(45.2%) 46(54.8%) 3.6(2.38,5.39) 2.2(1.43, 3.44) 0.000**
WHO stage
 Stage I &II 42(13.8%) 263(86.2%) 1 1
 Stage III&IV 59(32.2%) 124(67.8%) 2.1(1.43,3.16) 2.2(1.40,3.34) 0.000**
Treatment adherence
 Good 53(13.1%) 353(86.9%) 1 1
 Fair 12(31.6%) 26(68.4%) 2.8(1.50,5.26) 8.6(5.64, 2.2 (1.14,4.20) 0.019*
 Poor 36(81.8%) 8(18.2%) 13.2) 6.6(4.11,10.56) 0.000**

Notes: *Statistically significant predictors. **Statistically highly significant predictors.

Discussion

The incidence rate of this study was 6.3 per 100 children years of observation (CI=5.21, 7.77). Upon running the final Cox proportional hazard model, statistically significant predictors for LTFU were male sex, WHO stage III and IV, age between 1–5 years, stunting, poor and fair adherence to ART, and regimen not changed.

The overall incidence rate of this study is in line with the study conducted in Addis Ababa, Ethiopia: 6.26 per 100 children years of observation.25 On the other side, the result of this study is lower than the studies conducted in Tanzania which showed the incidence rate of LTFU was 18.2 per 100 children years of observation, Uganda 12.6 per 100 children years of observation, and in South Africa, 10.8 per 100 children years of observation.29,35,38 This difference might be due to socioeconomic and cultural difference, difference in study time because the government may devise different intervention strategies to alleviate the problem and health care policy. Besides, in Tanzania, the study included both pre-ART initiation and post-ART initiation children and in Uganda, a high presence of orphaned children was found in the study.

On the contrary, the result of this study is higher than studies conducted in Thailand: 2.92 per 100 children years of observation, and India: 4.4 per 100 children years of observation. This difference might be due to sociocultural, economic differences, differences in emphasis given by the government nationally, study setting and access to the service.39,40 The other possible explanation is the presence of more ART service decentralization in India. Additionally, in Thailand there is a difference in study participants, they included children who attended at least 12 months of ART clinic, and study period difference. Plus this, the result of this study is higher than studies conducted in Zimbabwe, 4.92 per 100 children years of observation, and 3.29 per 100 children years of observation in Kenya.13,36,41 This might be due to variation in the implementation of retention in care strategy and also follow-up period difference.

In this study, LTFU before 18 months (with an incidence rate of 6.6 per 100 children years of observation) was higher than LTFU after 18 months of ART initiation (6.1 per 100 children years of observation). This is due to the fact that, at the initial time, they are at risk for immune reconstitution inflammatory syndrome and drug side effects that increase the risk of death.

The incidence rate of loss to follow-up at the first year (6.9 per 100 children years of observation) was higher as compared to the second year (5.9 per 100 children years of observation). This is in line with the study conducted in South Africa.24 This is might be due to health care workers who give repeated counseling for caregivers about the benefit of ART treatment and the consequence of discontinuing. The other possible explanation might be that the government gives attention and creates awareness in the community about the benefit of treatment and decentralization of ART services.

The cumulative incidence of this study was 20.7% (CI=17.20, 23.80). This is in line with the studies conducted in West Africa, 21.8%, Nigeria, 19%, and Ethiopia, 17.9%.21,28,42 However, this result is higher than studies conducted in Asia, 4.1%, Côte d’Ivoire, 9.3%, East Africa, 14%, South Africa, 9%, and Zambia, 16%.21,27 This might be due to economic and sociodemographic differences and variation in the implementation of a retention strategy, accessibility of the service, and weak monitoring and evaluation system of the service. For example, in Zambia, health care workers apply home-to-home visits. On the contrary, the finding of this study is lower than studies conducted in Mozambique, 38.7% and in Adama Ethiopia, 34%.43,44 This might be because in Mozambique, the study was conducted in 10 rural districts and there was a challenge of transportation and poor health care infrastructure. In Adama Ethiopia, the study included both pre-ART initiation and post-ART initiation.

In this study, the hazard of loss to follow up among children between 1–5 years old was 1.6 times higher than children greater or equal to five years old. This is supported by studies conducted in Thailand and Botswana.39,45 It may be because this age group was more at risk for malnutrition and opportunistic infections that increase disease progression rapidly, which indirectly increases loss to follow up.37 This result is inconsistent with a comparative analysis study conducted in Asia and South Africa.21,24

This study showed that being male had 2.1 times increased risk of loss to follow up compared to female. This is consistent with studies conducted in Kenya, South Africa, and Brazil.13,24,32 This is because most (59.4%) males initiate ART at advanced stage of disease. Having advanced clinical stage (WHO stage III and IV) at the time of ART initiation significantly increased the hazard of loss to follow up among children. This is supported by studies conducted in West Africa, Malawi, Uganda, Botswana, and Ethiopia.29,42,45–47 The possible explanation might be that children who initiate ART in the advanced stage have an increased risk of opportunistic infections that cause morbidity and mortality of unregistered deaths. Moreover, children in the advanced stage may develop drug side effects, especially within the first six months and further complicate disease progression.48 On the other hand, this result is inconsistent with studies conducted in South Africa and Kenya.34,37 The possible explanation might be that patients with stage I and II do not feel sick enough to accept restrictive medical care.49 Additionally, in South Africa, children with this stage were asymptomatic, and health care workers might not give as much attention as to those with advanced disease.34

Children whose nutritional status was stunted were more at risk to loss to follow up as compared to those whose nutritional status was normal. This is supported by studies conducted in other parts of African countries.27,31,43 This could be because stunted children may have had poor baseline health and poor ART compliance as compared to normal. HIV by itself affects nutritional status and malnourished children are more affected by HIV and increased disease progression.50,51 Furthermore, stunted children may have had a concomitant opportunistic infection that prevented them from going to the health facility for a refill of drugs and some may have died from such condition.52

Regarding adherence to ART, those with poor adherence had about seven times increased risk of loss to follow up compared to those with good adherence. Also, the risk of LTFU among children who had fair adherence to ART was 2.2 times higher than their counterparts. This is because of the fact that poor/fair adherence increases viral load duplication and decreases drug effectiveness, thus, further suppressing the immune system and increasing opportunistic infection and disease progression.53 The other possible explanation might be that poor medication adherence causes HIV viral resistance and subsequent treatment failure. Moreover, children depend on their caregiver to get their care and due to this, if the child had poor improvement, caregivers might be feeling hopelessness or carelessness and loss from treatment cascade.

Furthermore, children whose regimen was not changed were four times more at risk to loss to follow-up compared to those whose regimen was changed. This might be because most of the old regimens have side effects that cause advanced disease and complications. AZT containing regimen causes anemia that increases the disease progression rapidly.54

As to policy implications, Ethiopia has achieved a remarkable reduction in AIDS-related death in achieving 2020’s national target based on a study report from further analysis of global burden of diseases 2017 data.55 There are no well-organized tracing mechanisms to see the outcome of HIV infected children lost from HIV care clinics. Our study indicates the incidence of LTFU of children on ART. It does not, however, touch on what was happening to those children detached from healthcare follow-up sites.

Conclusion

The incidence rate of loss to follow was high. Age 1–5 years, World Health Organization clinical stage III and IV, poor and fair adherence to ART, regimen not changed, male sex and stunting were at higher risk for loss to follow up. Therefore, close monitoring of the higher risk groups for loss to follow up highlighted in this study could decrease the rate of loss to follow up. Improving the adherence of children to ART and nutritional support for stunted children are recommended.

Acknowledgment

We would like to thank Bahir Dar University College of Medicine and Health sciences. We also thank Dessie referral hospital administration and ART clinic staff for their support.

Funding Statement

This research was funded by Bahir Dar University.

Abbreviations

AIDS, Acquired Immune Deficiency Syndrome; ART, Antiretroviral Therapy; HIV, Human Immunodeficiency Virus; LTFU, Lost to Follow UP; WHO, World Health Organization.

Data Sharing Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author Contributions

All authors contributed to proposal development, data collection, data analysis, drafting or revising the article, have agreed on the journal to which the article is to be submitted, reviewed and agreed on all versions of the article before submission, during revision and agree to take responsibility and be accountable for the contents of the article.

Disclosure

The authors report no conflicts of interest in this work.

References

  • 1.UNAIDS. Fact sheet – world AIDS day; 2019.
  • 2.World Health Organization. Global Health Observatory (GHO) Data; 2019. [Google Scholar]
  • 3.UNAIDS. Data; 2019.
  • 4.UNAIDS. Miles to Go—Closing Gaps, Breaking Barriers, Righting Injustices; 2018. [Google Scholar]
  • 5.Office FHAPaC. HIV Prevention in Ethiopia National Road Map 2018–2020; 2018. [Google Scholar]
  • 6.International. CSACEaI. Ethiopia Demographic and Health Survey HIV Report. Addis Ababa, Ethiopia, and Rockville, Maryland, USA; 2016. [Google Scholar]
  • 7.Institute Eph. HIV related estimate and projection for Ethiopia Addis Ababa; 2017. Available from:https://www.ephi.gov.et/images/pictures/download2009/HIVestimationandprojectionforEthiopia2017.pdf. Accessed December13, 2019.
  • 8.World Health Organization. Global Health Sector Strategy on Hiv 2016–2021 Towards Ending Aids; 2016. [Google Scholar]
  • 9.UNAIDS. 90-90-90 an Ambitious Treatment Target to Help End the AIDS Epidemic; 2014. [Google Scholar]
  • 10.Federal HIV/AIDS Prevention & Control Office E. HIV/AIDS Strategic Plan 2015–2020 in an Investment Case Approach; 2014. [Google Scholar]
  • 11.Crofts N, Patterson DPolice Must Join the Fast Track to End AIDS by 2030. Wiley Online Library; 2016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.World Health Organization. HIV/ADIS Department; 2017. [Google Scholar]
  • 13.Saumu WM, Maleche-Obimbo E, Irimu G, Kumar R, Gichuhi C, Karau B. Predictors of loss to follow-up among children attending HIV clinic in a hospital in rural Kenya. Pan Afr Med J. 2019;32(216). doi: 10.11604/pamj.2019.32.216.18310 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Egger M, Spycher B, Sidle J, Weigel R, Geng E. Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral; 2011. [DOI] [PMC free article] [PubMed]
  • 15.Hønge BL, Jespersen S, Nordentoft PB, et al. Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study. BMJ Open. 2013;3(10):e003499. doi: 10.1136/bmjopen-2013-003499 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kalembo FW, Zgambo M. Loss to followup: a major challenge to successful implementation of prevention of mother-to-child transmission of HIV-1 programs in sub-Saharan Africa. Int Sch Res Notices. 2012;2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.McNairy ML, Lamb MR, Carter RJ, et al. Retention of HIV-infected children on antiretroviraltreatment in HIV care and treatment programs in Kenya, Mozambique, Rwanda and Tanzania. J Acquir Immune Defic Syndr. 2012;62(70):81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Weiler G. Global Update on HIV Treatment 2013: Results, Impact and Opportunities. Geneva: World Health Organization; 2013:2017. [Google Scholar]
  • 19.Brinkhof MWG, Pujades-Rodriguez M, Egger M, Emery S. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One. 2009;4(6):e5790. doi: 10.1371/journal.pone.0005790 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Fox MP, Rosen S. Systematic review of retention of pediatric patients on HIV treatment in low and middle-income countries 2008–2013. Aids. 2015;29(4):493–502. doi: 10.1097/QAD.0000000000000559 [DOI] [PubMed] [Google Scholar]
  • 21.Leroy V, Malateste K, Rabie H, et al. Outcomes of antiretroviral therapy in children in Asia and Africa: a comparative analysis of the IeDEA pediatric multiregional collaboration. J Acquir Immune Defic Syndr. 2013;62(2):208. doi: 10.1097/QAI.0b013e31827b70bf [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Manuel K, Sibhatu IA, Feleke G. HIV case management in Ethiopia: a pragmatic approach to maximizing adherence to long-term treatment and retention in chronic illness care; 2014.
  • 23.Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. Can the UNAIDS 90-90-90target be achieved? A systematic analysis of national HIV treatment cascades. BMJ Glob Health. 2016;1(2):e000010. doi: 10.1136/bmjgh-2015-000010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Sengayi M, Dwane N, Marinda E, Sipambo N, Fairlie L, Moultrie H. Predictors of loss to follow-up among children in the first and second years of antiretroviral treatment in Johannesburg, South Africa. Glob Health Action. 2013;6(1):19248. doi: 10.3402/gha.v6i0.19248 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Mulatu Biru IH, Lundqvist P, Jerene D. Rates and predictors of attrition among children on antiretroviral therapy in Ethiopia: a prospective cohort study. PLoS One. 2018;13(2):e0189777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Miller CM, Ketlhapile M, Rybasack‐Smith H, Rosen S. Why are antiretroviral treatment patients lost to follow‐up? A qualitative study from South Africa. Trop Med Int Health. 2010;15:48–54. doi: 10.1111/j.1365-3156.2010.02514.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Mutanga JN, Mutembo S, Ezeamama AE, et al. Predictors of loss to follow-up among children on long-term antiretroviral therapy in Zambia (2003–2015). BMC Public Health. 2019;19(1):1120. doi: 10.1186/s12889-019-7374-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Ojikutu B, Higgins-Biddle M, Greeson D, et al. The association between quality of HIV care, loss to follow-up and mortality in pediatric and adolescent patients receiving antiretroviral therapy in Nigeria. PLoS One. 2014;9(7):e100039. doi: 10.1371/journal.pone.0100039 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Massavon W, Barlow-Mosha L, Mugenyi L, et al. Factors determining survival and retention among HIV-infected children and adolescents in a community home-based care and a facility-based family-centred approach in Kampala, Uganda: a cohort study. Isrn Aids. 2014;2014:1–13. doi: 10.1155/2014/852489 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Ditekemena J, Luhata C, Bonane W, et al. Antiretroviral treatment program retention among HIV-infected children in the Democratic Republic of Congo. PLoS One. 2014;9(12):e113877. doi: 10.1371/journal.pone.0113877 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Auld AF, Tuho MZ, Ekra KA, et al. Temporal trends in mortality and loss to follow-up among children enrolled in Cote d’Ivoire’s national antiretroviral therapy program. Pediatr Infect Dis J. 2014;33(11):1134–1140. doi: 10.1097/INF.0000000000000457 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Da Cruz Gouveia PADC, da Silva GAP, de Fatima Pessoa Militão de Albuque M. Predictors of loss to follow-up among children registered in an HIV prevention mother-to-child transmission cohort study in Pernambuco, Brazil. BMC Public Health. 2014;14(1):1232. doi: 10.1186/1471-2458-14-1232 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Hodgson I, Plummer ML, Konopka SN, et al. A systematic review of individual and contextual factors affecting ART initiation, adherence, and retention for HIV-infected pregnant and postpartum women. PLoS One. 2014;9(11):e111421. doi: 10.1371/journal.pone.0111421 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.UNAIDS U, and World Health Organization. The Incredible Journey of the Global Plan Towards the Elimination of New HIV Infections Among Children by 2015 and Keeping Their Mothers Alive; 2016. [Google Scholar]
  • 35.Chandiwana N, Sawry S, Chersich M, Kachingwe E, Makhathini B, Fairlie L. High loss to follow-up of children on antiretroviral treatment in a primary care HIV clinic in Johannesburg, South Africa. Medicine. 2018;97(29):29. doi: 10.1097/MD.0000000000010901 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Fetene T. Incidence and predictors of lost to follow upamong children on antiretroviral therapy at East and West Gojjam Zone referral hospitals, (2018); 2018.
  • 37.(EMOH) Emoh. National comprehensive HIV prevention, care and treatment training for health care providers; 2018.
  • 38.McCormick NM, Nan L, Sando D, et al. Risk factors of loss to follow up among HIV positive pediatric patients in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr. 2015;70(3):e73. doi: 10.1097/QAI.0000000000000782 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Teeraananchai S, Kerr SJ, Puthanakit T, et al. Attrition and mortality of children receiving antiretroviral treatment through the universal coverage health program in Thailand. J Pediatr. 2017;188:210–6. e1. doi: 10.1016/j.jpeds.2017.05.035 [DOI] [PubMed] [Google Scholar]
  • 40.Nimkar S, Valvi C, Kadam D, et al. Loss to follow‐up and mortality among HIV‐infected adolescents receiving antiretroviral therapy in Pune, India. HIV Med. 2018;19(6):395–402. doi: 10.1111/hiv.12605 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Kranzer K, Bradley J, Musaazi J, et al. Loss to follow‐up among children and adolescents growing up with HIV infection: age really matters. J Int AIDS Soc. 2017;20(1):21737. doi: 10.7448/IAS.20.1.21737 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Melaku Z, Lulseged S, Wang C, et al. Outcomes among HIV‐infected children initiating HIV care and antiretroviral treatment in Ethiopia. Trop Med Int Health. 2017;22(4):474–484. doi: 10.1111/tmi.12834 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Hagströmer O, Lundstedt L, Balcha TT, Björkman P. Decentralised paediatric HIV care in Ethiopia: a comparison between outcomes of patients managed in health centres and in a hospital clinic. Glob Health Action. 2013;6(1):22274. doi: 10.3402/gha.v6i0.22274 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Vermund SH, Blevins M, Moon TD, et al. Poor clinical outcomes for HIV infected children on antiretroviral therapy in rural Mozambique: need for program quality improvement and community engagement. PLoS One. 2014;9(10):e110116. doi: 10.1371/journal.pone.0110116 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Machine EM, Gillespie SL, Homedes N, et al. Lost to follow-up: failure to engage children in care in the first three months of diagnosis. AIDS Care. 2016;28(11):1402–1410. doi: 10.1080/09540121.2016.1179714 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Weigel R, Estill J, Egger M, et al. Mortality and loss to follow-up in the first year of ART: Malawi national ART programme. AIDS. 2012;26(3):365–373. doi: 10.1097/QAD.0b013e32834ed814 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Ekouevi DK, Azondekon A, Dicko F, et al. 12-month mortality and loss-to-program in antiretroviral-treated children: the IeDEA pediatric West African Database to evaluate AIDS (pWADA), 2000–2008. BMC Public Health. 2011;11(1):519. doi: 10.1186/1471-2458-11-519 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Assemie MA, Muchie KF, Ayele TA. Incidence and predictors of loss to follow up among HIV-infected adults at Pawi General Hospital, northwest Ethiopia: competing risk regression model. BMC Res Notes. 2018;11(1):287. doi: 10.1186/s13104-018-3407-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Bikoro B, Oljira L, Gobena T, Erkalo D. Incidence and predictors of loss to follow-up among human immunodeficiency virus-infected adult patients on anti-retroviral therapy at Hadiya zone public hospitals, Southern Ethiopia: a retrospective cohort study. J Public Health. 2020:1–12. [Google Scholar]
  • 50.Labban L. The implications of HIV/AIDS on the nutritional status and the MNT for its patients. EC Nutr. 2016;3:680–686. [Google Scholar]
  • 51.Duggal S, Chugh TD, Duggal AK. HIV and malnutrition: effects on immune system. Clin Dev Immunol. 2012;2012:1–8. doi: 10.1155/2012/784740 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Opio D, Semitala FC, Kakeeto A, et al. Loss to follow-up and associated factors among adult people living with HIV at public health facilities in Wakiso district, Uganda: a retrospective cohort study. BMC Health Serv Res. 2019;19(1):628. doi: 10.1186/s12913-019-4474-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Holtzman CW, Brady KA, Yehia BR. Retention in care and medication adherence: current challenges to antiretroviral therapy success. Drugs. 2015;75(5):445–454. doi: 10.1007/s40265-015-0373-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Gebremedhin KB, Haye TB. Factors associated with anemia among people living with HIV/AIDS taking ART in Ethiopia. Adv Hematol. 2019;2019:1–8. doi: 10.1155/2019/9614205 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Mirkuzie AH, Ali S, Abate E, Worku A, Misganaw A. Progress towards the 2020 fast track HIV/AIDS reduction targets across ages in Ethiopia as compared to neighboring countries using global burden of diseases 2017 data. BMC Public Health. 2021;21(1):1. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from HIV/AIDS (Auckland, N.Z.) are provided here courtesy of Dove Press

RESOURCES